Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Buys $435,993.84 in Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan bought 238,248 shares of Ventyx Biosciences stock in a transaction on Friday, November 22nd. The stock was purchased at an average price of $1.83 per share, for a total transaction of $435,993.84. Following the completion of the acquisition, the chief executive officer now owns 1,913,276 shares in the company, valued at $3,501,295.08. This represents a 14.22 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Raju Mohan also recently made the following trade(s):

• On Monday, November 25th, Raju Mohan purchased 261,752 shares of Ventyx Biosciences stock. The shares were purchased at an average price of $2.01 per share, with a total value of $526,121.52.

Ventyx Biosciences Trading Up 23.3 %

Shares of VTYX opened at $2.54 on Wednesday. Ventyx Biosciences, Inc. has a twelve month low of $1.67 and a twelve month high of $11.48. The firm has a market capitalization of $179.60 million, a P/E ratio of -1.08 and a beta of 0.37. The stock’s fifty day simple moving average is $2.19 and its 200 day simple moving average is $2.61.

Analyst Upgrades and Downgrades

VTYX has been the topic of a number of analyst reports. Wells Fargo & Company decreased their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. HC Wainwright restated a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a report on Monday, November 11th. Canaccord Genuity Group reduced their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Finally, Oppenheimer restated an “outperform” rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Hedge Funds Weigh In On Ventyx Biosciences

A number of large investors have recently modified their holdings of VTYX. Farallon Capital Management LLC acquired a new stake in Ventyx Biosciences during the 1st quarter worth approximately $17,435,000. Deerfield Management Company L.P. Series C grew its stake in Ventyx Biosciences by 64.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after buying an additional 2,287,570 shares during the period. Sio Capital Management LLC grew its stake in Ventyx Biosciences by 153.2% during the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock worth $4,299,000 after buying an additional 1,193,024 shares during the period. Ikarian Capital LLC increased its position in shares of Ventyx Biosciences by 8,483.8% in the first quarter. Ikarian Capital LLC now owns 507,647 shares of the company’s stock worth $2,792,000 after acquiring an additional 501,733 shares in the last quarter. Finally, Vestal Point Capital LP raised its stake in shares of Ventyx Biosciences by 31.2% in the 3rd quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $3,760,000 after acquiring an additional 410,000 shares during the period. 97.88% of the stock is currently owned by hedge funds and other institutional investors.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.